Page 154 - Haematologica - Vol. 105 n. 6 - June 2020

S. Ferrero et al.
evolution in mantle cell lymphoma. Proc Natl
Acad Sci U S A. 2013;110(45):18250-18255.
11. Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lym- phoma is related to the epigenetically determined chromatin state of normal B
cells. Blood. 2014;123(19):2988-2996.
12. Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strate- gies for mantle cell lymphoma. Nat Med.
2014;20(1):87-92.
13. Kumar A, Yang W, Bantilan KS, et al.
Prognostic significance of genomic alter- ations in mantle cell lymphoma. Blood. 2016;128(22):4115.
14. Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic informa- tion to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study. Br J Haematol. 2014;166(1):98-108.
15. Halldórsdóttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p dele- tion in mantle cell lymphoma. Leukemia. 2011;25(12):1904-1908.
16. Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not over- come the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604-611.
17. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903-1910.
18. Cortelazzo S, Martelli M, Ladetto M, et al. High dose sequential chemotherapy with
rituximab and ASCT as first line therapy in adult MCL patients: clinical and molecular response of the MCL0208 trial, a FIL study. Haematologica. 2015;100(s1):3-4.
in mantle cell lymphoma: technical aspects and clinical relevance. Semin Hematol. 2011;48(3):172-184.
27. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-
19. Swerdlow SH, Campo E, Pileri SA, et al.
The 2016 revision of the World Health Organization classification of lymphoid 586.
neoplasms. Blood. 2016;127(20):2375-2390 20. Meissner B, Kridel R, Lim RS, et al. The E3 ubiquitin ligase UBR5 is recurrently mutat- ed in mantle cell lymphoma. Blood.
2013;121(16):3161-3164.
21. Roccaro AM, Sacco A, Jimenez C, et al.
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lym- phoma. Blood. 2014;123(26):4120-4131.
22. Rinaldi A, Kwee I, Young KH, et al. Genome-wide high resolution DNA profil- ing of hairy cell leukaemia. Br J Haematol. 2013;162(4):566-569.
23. Kwee IW, Rinaldi A, de Campos CP, et al. Fast and robust segmentation of copy num- ber profiles using multi-scale edge detec- tion. BioRxiv. 2016. https:// doi.org/10.1101/056705.
24. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11(10):1793-1798.
25. Stamatopoulos K, Kosmas C, Belessi C, et al. Molecular analysis of bcl-1/IgH junction- al sequences in mantle cell lymphoma: potential mechanism of the t(11;14) chro- mosomal translocation. Br J Haematol. 1999;105(1):190-197.
26. Pott C. Minimal residual disease detection
28. Froimchuk E, Jang Y, Ge K. Histone H3 lysine 4 methyltransferase KMT2D. Gene. 2017;627:337-342.
29. Varettoni M, Zibellini S, Defrancesco I, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undeter- mined significance. Haematologica. 2017;102(12):2077-2085.
30. Spina V, Khiabanian H, Messina M, et al. The genetics of nodal marginal zone lym- phoma. Blood. 2016;128(10):1362-1373.
31. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
32. Malcikova J, Tausch E, Rossi D, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia- update on methodological approaches and results interpretation. Leukemia. 2018;32 (5):1070-1080.
33. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non- hodgkin lymphoma. J Clin Oncol. 2017;35(8):826-833.
34. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211-1223.
1612
haematologica | 2020; 105(6)